Crossject USA Inc.
CROSSJECT develops a needle-free, pre-filled, single-use auto-injector platform intended for rapid administration of emergency medications. The company focuses on device engineering, human factors, clinical development for emergency indications (epileptic seizures, acute adrenal crisis, anaphylaxis), and regulatory authorization efforts including engagement with U.S. government funding agencies.
Industries
N/A
Nr. of Employees
small (1-50)
Crossject USA Inc.
Products
Needle-free, pre-filled, single-use auto-injector platform
A needle-free, pre-filled, single-use auto-injector platform designed for rapid delivery of emergency medications without a needle.
Needle-free, pre-filled, single-use auto-injector platform
A needle-free, pre-filled, single-use auto-injector platform designed for rapid delivery of emergency medications without a needle.
Services
Clinical program planning and execution for device-delivered emergency therapies.
Regulatory planning and submission support focused on obtaining market authorization in the U.S. (FDA) and other jurisdictions.
User-centered testing and human factors validation for emergency-use device designs.
Clinical program planning and execution for device-delivered emergency therapies.
Regulatory planning and submission support focused on obtaining market authorization in the U.S. (FDA) and other jurisdictions.
User-centered testing and human factors validation for emergency-use device designs.
Expertise Areas
- Needle-free auto-injector device development
- Emergency medicine therapeutics (seizure rescue, adrenal crisis, anaphylaxis)
- Clinical program design for acute indications
- Regulatory strategy for FDA authorization
Key Technologies
- Needle-free auto-injector platform
- Pre-filled drug-device combination products
- Human factors-driven device design
- Rapid parenteral delivery alternatives to needles
News & Updates
Release of the company's financial results and summary of key developments for the first half of 2025.
Announcement of a successful equity capital increase totaling €5.7 million.
Secured additional funding from a U.S. government agency to support progressive development and FDA authorization of a midazolam auto-injector product.
Completed a successful capital increase of €5.7 million to support operations and development programs.
Obtained supplemental funding from a U.S. government health security agency to support development and FDA authorization activities for a midazolam auto-injector.
Release of the company's financial results and summary of key developments for the first half of 2025.
Announcement of a successful equity capital increase totaling €5.7 million.
Secured additional funding from a U.S. government agency to support progressive development and FDA authorization of a midazolam auto-injector product.
Completed a successful capital increase of €5.7 million to support operations and development programs.
Obtained supplemental funding from a U.S. government health security agency to support development and FDA authorization activities for a midazolam auto-injector.